Abbott has launched MOBILITY, a clinical trial studying the safety and efficacy of the Absolute Pro peripheral self-expanding stent system to treat iliac artery disease.
Lead researcher John Campbell, MD, of West Virginia University School of Medicine at the Charleston Area Medical Center in Charleston, W. Va., enrolled the first patient into the MOBILITY trial. The MOBILITY trial is designed to study 150 patients at approximately 50 centers in the U.S.
The Abbott Park, Ill.-based company said its primary endpoint is a composite measure of major adverse events (MAE) at nine months. MAE is defined as death due to any causes, MI, clinically-driven target lesion revascularization and limb loss on the treated side(s). The MOBILITY trial will be used as the basis for a peripheral vascular indication filing for the Absolute Pro peripheral stent.